CuraSen Therapeutics has commenced its Phase IIa proof-of-concept trial of CuraAX (CST-3056) with dosing of the first patient ...
A study conducted by researchers at the Center for Redox Processes in Biomedicine (Redoxoma) has shown that ATP-sensitive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback